Look back at pharma news in the week to October 8, 2021

10 October 2021

By Barbara Obstoj-Cardwell

Last week’s deal-making news featured Johnson & Johnson’s Janssen unit signing an agreement with US biotech Xencor for the latter’s XmAb B-cell targeting antibody plamotamab, potentially worth $1.3 billion. AstraZeneca last week filed for emergency use of its AZD7442 for the prophylaxis of symptomatic COVID-19 with the US Food and Drug Administration. On Wednesday, Japanese drug major Takeda admitted a setback with its orexin agonist program, when it paused a trial of TAK-994 after a safety issue. Also, US biotech Allogene had a disappointment last Thursday with the FDA placing a clinical hold on its ALLO-501A Phase III trial in cancer.

J&J breathes some more life into plamotamab and CD28

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK